"from Wen et al 1: "In the event there are interslice gaps, this also needs to be considered in determining the size of measurable lesions at baseline." [needs clarification]"
"Response assessment in neuro-oncology (RANO) criteria are used to assess response to first-line treatment of glioblastoma as well as lower-grade astrocytoma 1,3."
"The RANO criteria were published in 2010 and have largely superseded the older Macdonald criteria (which only dealt with glioblastoma) 2."
"RANO 2.0 was published in 2023 and seeks to unify various other RANO criteria (e.g., modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria) into a single framework."
"RANO 2.0 was published in 2023 and seeks to unify various other RANO criteria (e.g., modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria) into a single framework."
"RANO 2.0 was published in 2023 and seeks to unify various other RANO criteria (e.g., modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria) into a single framework."
"RANO 2.0 was published in 2023 and seeks to unify various other RANO criteria (e.g., modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria) into a single framework."
"The RANO criteria, roughly similar to other systems (cf. RECIST), divide response into four types, based on imaging (MRI) and clinical features 1,2:"
"The RANO criteria, roughly similar to other systems (cf. RECIST), divide response into four types, based on imaging (MRI) and clinical features 1,2:"
"The RANO criteria were, at least in part, developed to address the issues faced when measuring some lesions using Macdonald criteria, particularly:"
"Caveat: Within the first 12 weeks following chemoradiotherapy, progressive disease can only be defined radiographically when new enhancement is present beyond the original radiation field (high-dose region or 80% isodose line)."
Expected headings
"Measurement"
"Measurable lesions"
"Non-measurable lesions"
"Criteria"
"Complete response"
"Partial response"
"Stable disease"
"Progression"